A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1842 participants.

Also called NCT03495102

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,842 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03495102
  • EudraCT 2017-003490-33
Other papers using this trial's data
  • Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study Diabetes, obesity & metabolism, 2022-09 DOI, PubMed 35546790, PMC9543252 In the PMC Open Access subset under CC BY-NC.
  • Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) Diabetes care, 2021-03 DOI, PubMed 33397768, PMC7896253 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Canada, Greece, Hungary, Israel, Italy, Mexico, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03495102. Randomized; double masking; primary purpose treatment. Start 2018-04-05 (actual); primary completion 2019-05-28 (actual). Results posted on 2020-06-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
Acronym
AWARD-11
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dulaglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03495102
Content hash
a37d891bcf08bca465a6b099d83c618a8b0c9422a189ca3e8d930bc495cc5026